<DOC>
	<DOCNO>NCT00637715</DOCNO>
	<brief_summary>Collection data safety efficacy daily administration alfuzosin preparation /Alfetim UnoÂ® l0 mg/ patient low urinary tract symptoms/complaints render possible presence benign prostatic hyperplasia , course everyday practice</brief_summary>
	<brief_title>Once Daily Given Alfuzosin Treatment BPH</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Sexually active male patient low urinary tract symptom indicative severe BPH , disturbances urinary retention urination present Necessity surgical intervention immediately within 12 month BPH The patient earlier /within 6 months/ obtain treatment BPH The patient improve earlier alpha1 blocker treatment Known hypersensitivity alfuzosin Orthostatic hypotension history Concomitant application another alpha1 blocker Hepatic insufficiency /AST , ALT 3 fold upper limit normal value/ Severe renal insufficiency /se creatinine great equal 150 umol/l/ Intestinal obstruction /because castor oil content drug/ Tumorous disease Severe , life threaten state The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>